Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1712||SWOG||A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-70301||CALGB||Quality of Life; Employment; and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes: Companion to CALGB 40101||Adult CIRB - Late Phase Emphasis||Completed|
|A031702||Alliance||A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|N1048||NCCTG||N1048 (PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1314||SWOG||A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized; Muscle-Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E2100||ECOG||A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0303||SWOG||A Phase III Trial of Modified FOLFOX6 Versus CAPOX; with Bevacizumab (NSC-704865) or Placebo; as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|GOG-0213||GOG||A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865; IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive; Recurrent Ovarian; Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865; IND #113912)(12/19/2011) (10/01/12) NCT# 00565851||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-NCIC-CTG-MA.32.F||NSABP||Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E4599||ECOG||Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC||Adult CIRB - Late Phase Emphasis||Completed|